Molecular features and clinical implications of the heterogeneity in Chinese patients with HER2-low breast cancer
Abstract The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well understood, limiting its precise management in the era of antibody‒drug conjugates. To address this issue, we established a cohort of 434 Chinese patients with...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-08-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-023-40715-x |